期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets re......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
To better understand the level of knowledge and interest in 'diet and lifestyle' for cholesterol management and CVD prevention, European Atheroscleros......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
The 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacolo......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Background and aims: Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Background and aim: To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients. Methods: A nationwide cross-s......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still under diagnosed and undertreated in the general population.......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
The availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite tha......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Post-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
Background and aim: The metabolic syndrome (MetS) has become one of the most important clinical issues in the cardiovascular field for this decade bec......
期刊： ATHEROSCLEROSIS SUPPLEMENTS, 2020; 42 ()
The evidence of the causal role of low-density lipoprotein cholesterol in the development of atherosclerotic cardiovascular disease is well-establishe......
